Quick Takeaways
- This page summarizes Christopher B. Ehrlich's Form 4 filing for eFFECTOR Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 13 Jun 2024, 18:25.
Christopher B. Ehrlich - 13 Jun 2024 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.
- Role
- Director
- Signature
- /s/ Michael Byrnes, Attorney-in-Fact for Christopher B. Ehrlich
- Issuer symbol
- N/A
- Transactions as of
- 13 Jun 2024
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 13 Jun 2024, 18:25:33 UTC
- Previous filing
- 27 Mar 2024
- Next filing
- 11 Jul 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Christopher B. Ehrlich filed Form 4 for eFFECTOR Therapeutics, Inc. on 13 Jun 2024."
What Changed
- Previous filing in this sequence was filed on 27 Mar 2024.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EFTR | Stock Option (Right to Buy) | Award | $0 | +800 | $0.000000 | 800 | 13 Jun 2024 | Common Stock | 800 | $1.38 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. |